GeoVax Labs, Inc. (Nasdaq: GOVX) is positioning its Gedeptin immuno-oncology program as a potential solution to a major challenge in cancer treatment: overcoming resistance to checkpoint inhibitors in immunologically cold tumors. The Atlanta-based clinical-stage biotechnology company highlighted the strategic relevance of Gedeptin within the evolving landscape of combination immunotherapy, particularly its ability to modulate the tumor microenvironment and enhance responsiveness to PD-1 and PD-L1 inhibitors.
Checkpoint inhibitors have transformed cancer care, but many solid tumors remain unresponsive due to immune-suppressive environments, insufficient immune-cell infiltration, and incomplete tumor antigen recognition. According to GeoVax, Gedeptin's unique mechanism of localized tumor destruction combined with immune activation addresses these barriers. David Dodd, Chairman and CEO of GeoVax, stated, “Modern immuno-oncology is increasingly shifting toward combination strategies designed to improve the effectiveness of checkpoint inhibitors across broader patient populations. We believe Gedeptin aligns directly with this trend by functioning not simply as a localized tumor therapy, but as a potential immune-sensitization platform.”
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) that uses a non-replicating adenoviral vector to deliver purine nucleoside phosphorylase (PNP) into tumor tissue. After administration of fludarabine, the PNP enzyme converts the prodrug into a localized cytotoxic agent, destroying tumor cells while generating immune-activating signals. Key characteristics include a tumor-agnostic mechanism, strong bystander effect, tumor microenvironment remodeling, and compatibility with image-guided delivery.
GeoVax’s lead development focus is a planned neoadjuvant combination study in recurrent head and neck squamous cell carcinoma (HNSCC). The study will evaluate intratumoral Gedeptin together with a PD-1 targeting immunotherapy in patients eligible for curative-intent surgery, assessing pathologic response, immune biomarker modulation, and early event-free survival signals.
“The oncology field is increasingly recognizing that durable checkpoint inhibitor responses may require direct modulation of the tumor microenvironment in addition to checkpoint blockade alone,” Dodd added. “We believe Gedeptin’s ability to induce localized tumor destruction while simultaneously promoting immune activation creates a compelling rationale for combination development approaches designed to broaden and deepen immunotherapy responses.”
Beyond head and neck cancer, GeoVax sees potential for Gedeptin in tumors with established checkpoint inhibitor paradigms, incomplete response durability, or suppressed microenvironments, including melanoma, triple-negative breast cancer, and cutaneous malignancies. The company aims to position Gedeptin as a differentiated immune-enabling platform with broad applicability.
For more information about GeoVax and its programs, visit www.geovax.com.
